1-6 of 368 Activities
In this CME Outfitters Snack, expert faculty and a patient advocate will discuss clinical experience, study information, updates to guidelines, resources, and how to integrate sensitive and respectful discussions about anal cancer risk, prevention, and screening into everyday clinical workflows to improve outcomes for patients at high risk for anal cancer.
In this CME Outfitters chapter series, expert faculty will discuss strategies for identifying disparities when caring for persons of color living with HIV, communicating about HIV risk with patients from diverse backgrounds, and develop long-term, personalized care plans that include rapid initiation of antiretroviral therapies (ARTs) and support for treatment adherence for PLWH.
This CMEO Journal Club will equip HCPs with the latest evidence from recent clinical trials and scientific literature, enabling them to evaluate new prophylactic strategies and incorporate non-factor therapies into comprehensive, individualized treatment plans. Expert faculty will translate data into real-world insights to support improved patient outcomes and long-term disease management.
In this CMEO recorded webcast, expert faculty will present and discuss advances in non-factor therapies for hemophilia, including advancements in laboratory and monitoring practices and how to use shared decision-making (SDM) with patients to design individualized care plans that incorporate non-factor replacement therapies into treatment.
Immunoglobulin A nephropathy (IgAN) is a progressive glomerular disease and a leading cause of chronic kidney disease (CKD), with up to 40% of patients advancing to kidney failure within two decades. Despite guideline-recommended management emphasizing supportive care and RAAS inhibition, many patients continue to experience persistent proteinuria and declining renal function. Clinical practice remains inconsistent, particularly regarding the use of assessment tools and initiation of immunosuppressive therapies. While updated risk scoring models, AI-driven risk stratification tools, and biomarker-guided assessments have emerged, awareness and utilization in routine care are limited. As new therapies enter practice, clinicians require practical education to incorporate evolving evidence into patient care. To meet this need, a virtual journal club series will deliver concise, case-based learning that translates recent clinical trial findings into actionable strategies. This format is designed to foster reflection, support informed decision-making, and help nephrologists and other HCPs optimize treatment pathways for patients living with IgAN.
In this CME Outfitters recorded webcast, expert faculty will discuss the role of FcRn in the pathogenesis of gMG, evaluate the safety and efficacy of FcRn antagonists for the treatment of gMG, and provide expert guidance on how to identify patients with gMG who may be appropriate candidates for treatment with FcRn antagonists. Finally, they will model development of optimized and individualized treatment plans for patients with gMG receiving FcRn antagonists, providing learners with key skills to bring back to clinical practice.
